Sort   by:  
 Page size 
MetabolomicsA blood-based metabolic signature for earlier detection of lung cancer

Metabolomic profiling was applied to 1,259 sera collected within five years of a lung cancer diagnosis and 8,470 non-case sera from ever-smoker participants in the Prostate Lung Colorectal and Ovarian (PLCO) Study to identify metabolic signatures for the earlier detection of lung cancer. We devel...

2026-08-20 | MTBLS15406 | MetaboLights
MetabolomicsContributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer

BACKGROUND Increasing evidence implicates microbiome involvement in the development and progression of pancreatic ductal adenocarcinoma (PDAC). Studies suggest that reflux of gut or oral microbiota can lead to colonization in the pancreas, resulting in dysbiosis that culminates ...

2023-08-09 | MTBLS7260 | MetaboLights
MetabolomicsVesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer

Selective autophagy of mitochondria is known to promote survival and progression of cancer cells in various malignancies, including triple-negative breast cancer (TNBC). Here, we investigate the essential metabolic adaptations that support mitochondrial quality control in cancer cells with the ai...

2025-09-30 | MTBLS13037 | MetaboLights
ProteomicsHuman HER2-breast cancer cell line, trastuzumab-resistant, LC-MSMS
We established an acquired trastuzumab-resistant model in vitro from a trastuzumab-sensitive, HER2-amplified breast-cancer cell line. A multi-omic strategy was implemented to obtain gene, proteome, and phosphoproteome signatures associated with acquired resistance to trastuzumab in HER2-positive bre...
ORGANISM(S): Homo sapiens (Human) 
2020-06-01 | PXD010574 | Pride
Human Breast cancer Lc-msms Silac 
MetabolomicsMulti-omics of the gut microbial ecosystem in the immunotherapy resistance in microsatellite instability-high gastrointestinal cancer patients
Despite the encouraging efficacy of anti-PD-1/PD-L1 immunotherapy in microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) advanced gastrointestinal cancer, many patients exhibit primary or acquired resistance. Using multi-omics approaches, we interrogated gut microbiome, blood meta...
2026-07-16 | MTBLS9021 | MetaboLights
ProteomicsHuman pancreatic cancer LC-MSMS
This project aims to research protein-protein interaction of pancreatic cancer cells under different DNA replication pressure.
ORGANISM(S): Homo sapiens (Human) 
2022-09-20 | PXD032951 | Pride
Human Lc-msms Pancreatic cancer cells 
ProteomicsTargeting kinome reprogramming in ESR1 fusion-driven breast cancer
Multiplexed, deep-scale LC-MSMS analysis for proteome and phosphoproteome expression profile and the targeted LC-MSMS analysis for kinases in enriched kinome of the ER+ breast cancer patient-derived xenograft tumors.
ORGANISM(S): Mus musculus (Mouse) Homo sapiens (Human) 
2023-10-24 | PXD036644 | Pride
Lc-msms Esr1 fusion Breast cancer Breast cancer patient-derived xenograft (pdx) tumor Proteome Phosphoproteome 
ProteomicsHuman, ovarian epithelial cancer cell line, LC-MSMS
We investigated the functions of ECM1 subtypes ECM1a (inlcuding wild type and mutant) and ECM1b in ovarian cancer cell line HEYA8. While ECM1a is oncogenic, ECM1b is a tumor suppressor. To identify the molecules binding to ECM1a or ECM1b within cells, protein samples were generated by co-IP using HA...
ORGANISM(S): Homo sapiens (Human) 
2021-05-27 | PXD025239 | Pride
Human Ecm1 subtypes Ecm1a wild type (wt) Ecm1b Ecm1a mutant (mt) Ovarian epithelial cell line 
ProteomicsHuman colon cancer cell lines - LC-MSMS
Despite the advent of mutant-selective KRAS inhibitors, colorectal cancer (CRC) responses remain limited, with frequent stable disease and rapid recurrence. The mechanisms underlying CRC tolerance to KRAS inhibition and eventual resistance are poorly understood. Here, we explored early transcription...
ORGANISM(S): Homo sapiens (Human) 
2025-05-07 | PXD059013 | Pride
Human Lc-msms Resistant Colon cancer Kras silencing 
ProteomicsHuman pancreatic cancer LC-MSMS
Despite decades of effort, pancreatic adenocarcinoma (PDAC) remains an intractable clinical challenge. An insufficient understanding of mechanisms underlying tumor cell responses to chemotherapy contributes significantly to the lack of effective treatment regimens. Here, paclitaxel, a first-line che...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2018-08-31 | MSV000082878 | MassIVE
Sort   by:  
 Page size